TFDA approves import of anti-viral drug remdesivir to ensure treatment of patients with severe COVID-19

On May 30, the Central Epidemic Command Center (CECC) announced that Taiwan Food and Drug Administration (TFDA) approved, subject to certain conditions, the importation with permission of anti-viral drug remdesivir for the treatment of patients with severe SARS-CoV-2 infection in accordance with Article 48-2 of the Pharmaceutical Affairs Act. The TFDA’s decision is based on the needs of domestic public health and balance of risks. The CECC reported that remdesivir is approved as there is preliminary evidence indicating its positive effect and safety in treating COVID-19 patients, and it has gradually been approved for use in the international community. The approval of the importation of remdesivir can ensure patients’ rights to receive the medical treatment and proactively respond to the possible developments of the COVID-19 outbreak.